ADC shrinks brain metastases in HER2+ breast cancer patients
Phase II results show a high intracranial response rate in…
Phase II results show a high intracranial response rate in breast cancer patients with active brain metastases treated with trastzumab deruxtecan (T-Dxd), an antibody-drug conjugate (ADC).